Scarica l'app Stockscreener
0.86
6.88%
0.048
Precedente Chiudi:
$0.812
Aprire:
$0.82
Volume 24 ore:
46,509
Relative Volume:
0.31
Capitalizzazione di mercato:
$16.30M
Reddito:
$6.56M
Utile/perdita netta:
$-14.92M
Rapporto P/E:
-1.5926
EPS:
-0.54
Flusso di cassa netto:
$-33.87M
1 W Prestazione:
+45.38%
1M Prestazione:
+57.80%
6M Prestazione:
+41.12%
1 anno Prestazione:
-1.02%
Intervallo 1D:
$0.7942
$0.8799
Intervallo di 1 settimana:
$0.582
$0.8799
Portata 52W:
$0.334
$1.65
Sol Gel Technologies Ltd Stock (SLGL) Company Profile
Nome
Sol Gel Technologies Ltd
Settore
Industria
Telefono
-
Indirizzo
-
Confronta SLGL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SLGL
Sol Gel Technologies Ltd
|
0.8634 | 16.30M | 6.56M | -14.92M | -33.87M | -0.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
506.00 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.83 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
631.43 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
258.51 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
248.80 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Sol Gel Technologies Ltd Stock (SLGL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-19 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2022-10-21 | Ripresa | Jefferies | Hold |
| 2019-12-31 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-31 | Reiterato | JMP Securities | Mkt Outperform |
Sol Gel Technologies Ltd Borsa (SLGL) Ultime notizie
Basal Cell Nevus Syndrome Treatment Market 2032: EMA, PDMA, FDA - openPR.com
Sol-Gel Technologies Ltd [SLGL] Investment Guide: What You Need to Know - knoxdaily.com
Did Sol-Gel Technologies Ltd (SLGL) perform well in the last session? - uspostnews.com
Sol-Gel secures $16 million, extends cash runway By Investing.com - Investing.com Canada
Sol-Gel Technologies Secures $16 Million Deal with Mayne Pharma for U.S. Rights to EPSOLAY and TWYNEO - TipRanks
Sol-Gel secures $16 million, extends cash runway - Investing.com Australia
Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S. - The Manila Times
Sol-Gel's Strategic Pivot: $16M Product Sale Funds Promising Cancer Drug Development - Stock Titan
XBiotech Inc. (NASDAQ:XBIT) Shares Sold by American Century Companies Inc. - Defense World
Raymond James Financial Inc. Invests $101,000 in Sol-Gel Technologies Ltd. (NASDAQ:SLGL) - Defense World
Raymond James Financial Inc. Purchases New Shares in Stereotaxis, Inc. (NYSEAMERICAN:STXS) - Defense World
American Century Companies Inc. Sells 20,635 Shares of AxoGen, Inc. (NASDAQ:AXGN) - Defense World
Sol-Gel Technologies Ltd. (4SG.F) latest stock news and headlines - Yahoo
Investors Don't See Light At End Of Sol-Gel Technologies Ltd.'s (NASDAQ:SLGL) Tunnel And Push Stock Down 31% - simplywall.st
Acne Vulgaris Market to Reach New Heights in Growth by 2034, - openPR.com
Sol-Gel Technologies Approves Reverse Share Split and Compensation Policy Renewal - TipRanks
(PDF) NaFePO4 Particles as a Cathode of Sodium Ion-Battery via Sol-Gel Method: A Review on Synthesis - ResearchGate
Acne Market on Track for Major Expansion by 2032, According to DelveInsight | Clinuvel Pharma, Novan, Dermata Therapeutics, ioPharmX, Bausch Health Americas, Inc., Kintor Pharma, Sol-Gel Technologies - Barchart
Acne Market on Track for Major Expansion by 2032, According - openPR
Sol Gel Technologies Ltd expected to post a loss of 11 cents a shareEarnings Preview - TradingView
Actinic Keratosis Market Forecast 2034: EMA, PDMA, FDA Approvals, Prevalence, Clinical Trials, Treatment, Medication, Therapies, and Companies by DelveInsight - The Globe and Mail
Retinoic Acid Receptor Alpha Market Unlocking Growth Opportunities Through Smart Solutions - expressvartha.in
Uremic Pruritus Clinical and Non-Clinical Studies, Key - openPR
Sol-Gel Technologies (SLGL) to Release Quarterly Earnings on Wednesday - Defense World
Key Driver Transforming The Rosacea Market 2025: Rising Skin Disease Prevalence Fuels Growth In The Rosacea... - WhaTech
Acne Market Predicted to See Upsurge Through 2032, Highlights - openPR
Palmoplantar Keratoderma Clinical and Non-Clinical Studies, - openPR
Sol-Gel Coatings Market Trends, Insights, and Opportunities through 2032 - newstrail.com
Personalis (PSNL) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
SLGL Gears Up to Report Q4 Earnings: Here's What You Should Know - MSN
Supernus Pharmaceuticals (SUPN) Beats Q4 Earnings and Revenue Estimates - Yahoo Finance
Sol-Gel Technologies Schedules Shareholder Meeting to Vote on Key Proposals - TipRanks
Basal Cell Nevus Syndrome Treatment Market Size in the 7MM - openPR
Biotech Stocks Facing FDA Decision In August 2021 - RTTNews
Sol-Gel Technologies Ltd (SLGL) Shares Decline Despite Market Challenges - The News Heater
Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Not Doing Enough For Some Investors As Its Shares Slump 51% - Simply Wall St
Is Sol-Gel Technologies (NASDAQ:SLGL) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Constellium SE’s (CSTM) Stock: A -3.86% Simple Moving Average for the Past 20 Days - The News Heater
Tronox Holdings plc (TROX): A Technical Analysis - The News Heater
PreveCeutical to Develop Sol-Gel N2B Platform for Parkinson's Disease - Yahoo Finance
Rosacea Clinical Trials Analysis 2025: EMA, PDMA, FDA - openPR
Appointment of Dr. Bryan Jones as an Advisor to Lead Sol-Gel Special Projects - Yahoo Finance
Pre-market Movers: SLGL, VIRX, ANVS, CUTR... - RTTNews
Acne Vulgaris Market Size to Reach USD 10.4 Billion by 2035, with a Growth Rate (CAGR) of 3.33% during 2025-2035 - BioSpace
(PDF) Synthesis and Characterization of CZTS Thin Films by Sol-Gel Method without Sulfurization - ResearchGate
Rosacea Pipeline Analysis, Clinical Trials, EMA, PDMA, FDA - openPR
Actinic Keratosis Treatment Market 2034: EMA, PDMA, FDA Approvals, Prevalence, Clinical Trials, Medication, Therapies, and Companies by DelveInsight - The Globe and Mail
Acne Vulgaris Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, MOA, ROA by DelveInsight | Dermata Therapeutics, AstraZeneca, Novartis, UCB Pharma, Incyte Inc., Galderma - The Globe and Mail
Pre-market Movers: AVGR, TIVC, ATNF, SLGL... - RTTNews
DFD-29: The Journey to FDA Approval and a New Era in Rosacea Management - Dermatology Times
Acne Vulgaris Market Expected to Experience Major Growth by 2034, According to DelveInsight - EIN News
Sol Gel Technologies Ltd Azioni (SLGL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.36%
0.60%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):